AUPO755097A0 - Receptor agonist and antagonist - Google Patents

Receptor agonist and antagonist

Info

Publication number
AUPO755097A0
AUPO755097A0 AUPO7550A AUPO755097A AUPO755097A0 AU PO755097 A0 AUPO755097 A0 AU PO755097A0 AU PO7550 A AUPO7550 A AU PO7550A AU PO755097 A AUPO755097 A AU PO755097A AU PO755097 A0 AUPO755097 A0 AU PO755097A0
Authority
AU
Australia
Prior art keywords
antagonist
receptor agonist
protein
coupled receptors
modulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPO7550A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Priority to AUPO7550A priority Critical patent/AUPO755097A0/en
Publication of AUPO755097A0 publication Critical patent/AUPO755097A0/en
Priority to JP50515499A priority patent/JP4686696B2/ja
Priority to DK98930536T priority patent/DK1017713T3/da
Priority to HK01100346.0A priority patent/HK1029595B/en
Priority to PCT/AU1998/000490 priority patent/WO1999000406A1/en
Priority to EP98930536A priority patent/EP1017713B1/en
Priority to DE69838678T priority patent/DE69838678T2/de
Priority to ES98930536T priority patent/ES2294816T3/es
Priority to US12/045,088 priority patent/USRE41287E1/en
Priority to PT98930536T priority patent/PT1017713E/pt
Priority to AU80926/98A priority patent/AU744991B2/en
Priority to US09/446,109 priority patent/US6821950B1/en
Priority to AT98930536T priority patent/ATE377606T1/de
Priority to US10/937,852 priority patent/US20060160726A1/en
Priority to CY20081100033T priority patent/CY1107133T1/el
Priority to US12/193,943 priority patent/US20090203760A1/en
Priority to US13/348,869 priority patent/US20130005644A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
AUPO7550A 1997-06-25 1997-06-25 Receptor agonist and antagonist Abandoned AUPO755097A0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
AUPO7550A AUPO755097A0 (en) 1997-06-25 1997-06-25 Receptor agonist and antagonist
AT98930536T ATE377606T1 (de) 1997-06-25 1998-06-25 Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren
US12/045,088 USRE41287E1 (en) 1997-06-25 1998-06-25 Cyclic agonists and antagonists of C5A receptors and G Protein-coupled receptors
AU80926/98A AU744991B2 (en) 1997-06-25 1998-06-25 Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors
HK01100346.0A HK1029595B (en) 1997-06-25 1998-06-25 Cyclic antagonists of c5a receptors and g protein-coupled receptors
PCT/AU1998/000490 WO1999000406A1 (en) 1997-06-25 1998-06-25 CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS
EP98930536A EP1017713B1 (en) 1997-06-25 1998-06-25 CYCLIC ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS
DE69838678T DE69838678T2 (de) 1997-06-25 1998-06-25 ZYKLISCHE ANTAGONISTEN DER C5a REZEPTOREN SOWIE DER G-PROTEIN GEKOPPELTEN REZEPTOREN
ES98930536T ES2294816T3 (es) 1997-06-25 1998-06-25 Antagonistas ciclicos de receptores de c5a y receptores acoplados a proteinas g.
JP50515499A JP4686696B2 (ja) 1997-06-25 1998-06-25 Ｃ５ａ受容体およびＧタンパク質結合受容体の環状アゴニストおよびアンタゴニスト
PT98930536T PT1017713E (pt) 1997-06-25 1998-06-25 Antagonistas cíclicos de receptores de c5a e de receptores acoplados à proteína g
DK98930536T DK1017713T3 (da) 1997-06-25 1998-06-25 Cykliske antagonister af C5a-receptorer og G-protein-koblede receptorer
US09/446,109 US6821950B1 (en) 1997-06-25 1998-06-25 Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors
US10/937,852 US20060160726A1 (en) 1997-06-25 2004-09-10 Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors
CY20081100033T CY1107133T1 (el) 1997-06-25 2008-01-10 Κυκλικοι ανταγωνιστες των υποδοχεων c5a και συζευγμενοι με πρωτεϊνη g υποδοχεις
US12/193,943 US20090203760A1 (en) 1997-06-25 2008-08-19 CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS
US13/348,869 US20130005644A1 (en) 1997-06-25 2012-01-12 Cyclic agonists and antagonists of c5a receptors and g protein-coupled receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO7550A AUPO755097A0 (en) 1997-06-25 1997-06-25 Receptor agonist and antagonist

Publications (1)

Publication Number Publication Date
AUPO755097A0 true AUPO755097A0 (en) 1997-07-17

Family

ID=3801840

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPO7550A Abandoned AUPO755097A0 (en) 1997-06-25 1997-06-25 Receptor agonist and antagonist
AU80926/98A Ceased AU744991B2 (en) 1997-06-25 1998-06-25 Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU80926/98A Ceased AU744991B2 (en) 1997-06-25 1998-06-25 Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors

Country Status (11)

Country Link
US (5) USRE41287E1 (OSRAM)
EP (1) EP1017713B1 (OSRAM)
JP (1) JP4686696B2 (OSRAM)
AT (1) ATE377606T1 (OSRAM)
AU (2) AUPO755097A0 (OSRAM)
CY (1) CY1107133T1 (OSRAM)
DE (1) DE69838678T2 (OSRAM)
DK (1) DK1017713T3 (OSRAM)
ES (1) ES2294816T3 (OSRAM)
PT (1) PT1017713E (OSRAM)
WO (1) WO1999000406A1 (OSRAM)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPQ339899A0 (en) 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
CN1231464C (zh) 2000-08-10 2005-12-14 三菱制药株式会社 新型3－取代的脲衍生物及其药学应用
WO2002022556A1 (en) 2000-09-14 2002-03-21 Mitsubishi Pharma Corporation Novel amide derivatives and medicinal use thereof ugs
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
JP4290564B2 (ja) 2002-03-19 2009-07-08 チルドレンズ ホスピタル メディカル センター Ｃ５ａアナフィラトキシンの突然変異タンパク質、このような突然変異タンパク質をコードする核酸分子ならびにＣ５ａアナフィラトキシンの突然変異タンパク質の医薬的使用
JP2005530719A (ja) * 2002-03-29 2005-10-13 ニューロジェン コーポレーション 病原性炎症要素を有する状態の治療のための組み合わせ療法
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002950657A0 (en) 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2003266858B2 (en) * 2002-10-11 2006-09-14 Vast Bioscience Pty Limited Classes of compounds that interact with GPCRs
AU2002951995A0 (en) 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
ATE509632T1 (de) * 2002-10-16 2011-06-15 Promics Pty Ltd Behandlung von entzündlicher darmerkrankung
AU2002952129A0 (en) * 2002-10-17 2002-10-31 The University Of Queensland Treatment of hypersensitivity conditions
AU2003902354A0 (en) * 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
AU2003902586A0 (en) * 2003-05-26 2003-06-12 The University Of Queensland Treatment of burns
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
EP1498422A1 (de) * 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
CA2579678A1 (en) * 2004-10-04 2006-04-13 Alchemia Limited Selective inhibitors
AU2006205830A1 (en) * 2005-01-17 2006-07-20 Jerini Ag C5a receptor antagonists
DE602006019948D1 (de) * 2005-03-11 2011-03-17 Potentia Pharmaceuticals Inc Koppelten rezeptors zur behandlung von makuladegeneration
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
AU2008214359B2 (en) 2007-02-05 2014-01-16 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
US20110092446A1 (en) * 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
JP2011526738A (ja) * 2008-07-02 2011-10-13 サンゴバン・パフォーマンス・プラスティックス・シェンヌー 枠付き装置、封止材およびその製造方法
US9447176B2 (en) 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP2525814A4 (en) * 2010-01-22 2013-09-11 Univ Louisville Res Found METHOD FOR THE TREATMENT OR PREVENTION OF PARODONTITIS AND DISORDERS ASSOCIATED WITH PARODONTITIS
JP6022441B2 (ja) 2010-04-30 2016-11-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗Ｃ５ａ抗体およびその抗体の使用のための方法
US9895411B2 (en) * 2010-06-29 2018-02-20 San Diego State University Research Foundation Analogs of C5a and methods of using same
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
EP2723361B1 (en) 2011-06-22 2019-10-30 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
WO2014043223A1 (en) * 2012-09-11 2014-03-20 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
EP3929206A1 (en) 2012-11-15 2021-12-29 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2014248252A1 (en) * 2013-04-02 2015-10-29 M. Reza Ghadiri Uses of cyclic peptides for treating and preventing atherosclerosis
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
CA3287719A1 (en) 2015-10-07 2026-03-02 Apellis Pharmaceuticals, Inc. Use of long-acting compstatin analog for treating a complement-mediated disorder
MA45770A (fr) 2016-07-29 2019-06-05 Pfizer Peptides cycliques en tant qu'antagonistes du récepteur c5
WO2018081400A1 (en) 2016-10-27 2018-05-03 Alexion Pharmaceuticals Inc. Assay for c5b-9 deposition in complement-associated disorders
EP3978523A1 (en) 2017-04-03 2022-04-06 InflaRx GmbH Treatment of inflammatory diseases with inhibitors of c5a activity
CN116059313A (zh) 2017-04-07 2023-05-05 阿佩利斯制药有限公司 给药方案以及相关组合物和方法
CN111201241A (zh) 2017-06-23 2020-05-26 因弗拉克斯有限责任公司 用C5a活性抑制剂治疗炎性疾病
KR20240167712A (ko) 2017-12-15 2024-11-27 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
US20220356234A1 (en) 2019-10-02 2022-11-10 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
BR112022019090A2 (pt) 2020-03-27 2022-11-08 Inflarx Gmbh Inibidores de c5a para o tratamento de infecção por coronavírus
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
EP4150338A1 (en) 2020-05-15 2023-03-22 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
WO2024238422A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
WO2024238421A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of biomarkers for the identification and treatment of complement-mediated disorders
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5386011A (en) * 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
HUT75990A (en) 1993-12-06 1997-05-28 Ciba Geigy Ag C5a receptor antagonists having substantially no agonist activity
US5807824A (en) 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5614370A (en) * 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis

Also Published As

Publication number Publication date
WO1999000406A1 (en) 1999-01-07
DK1017713T3 (da) 2008-02-11
EP1017713B1 (en) 2007-11-07
US20090203760A1 (en) 2009-08-13
CY1107133T1 (el) 2012-10-24
DE69838678T2 (de) 2008-10-30
ES2294816T3 (es) 2008-04-01
EP1017713A1 (en) 2000-07-12
AU8092698A (en) 1999-01-19
EP1017713A4 (en) 2002-07-24
PT1017713E (pt) 2007-12-18
USRE41287E1 (en) 2010-04-27
ATE377606T1 (de) 2007-11-15
JP4686696B2 (ja) 2011-05-25
JP2002508767A (ja) 2002-03-19
US20130005644A1 (en) 2013-01-03
US20060160726A1 (en) 2006-07-20
AU744991B2 (en) 2002-03-07
DE69838678D1 (de) 2007-12-20
HK1029595A1 (en) 2001-04-06
US6821950B1 (en) 2004-11-23

Similar Documents

Publication Publication Date Title
DE69838678D1 (de) ZYKLISCHE ANTAGONISTEN DER C5a REZEPTOREN SOWIE DER G-PROTEIN GEKOPPELTEN REZEPTOREN
YU34898A (sh) Antagonisti ccr-3 receptora
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
NO983431L (no) Anti-klöemidler
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
WO1999048523A3 (en) Antagonists of the inflammatory mediator oncostatin m (osm)
MY137457A (en) Cyclic peptides having melanocortin-4 receptor agonist activity
EA199900630A1 (ru) Антагонисты рецепторов витронектина
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
CO5460266A1 (es) Novedosos analogos de la somatostatina
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics
SE9702002D0 (sv) Novel compounds
AUPN646795A0 (en) Neuropeptide Y-Y5 receptor
IT1270612B (it) Derivati eterociclo-condensatori di morfinoidi
SE9702794D0 (sv) New compounds
PT1042320E (pt) Novos compostos que sao antagonistas de receptores duplos de ourinoceptores p2 e de proteina g 7-transmembranar
DE60015187D1 (de) Urotensin-ii rezeptorantagonisten
EA200000197A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
DE69526738D1 (de) Endothelin-rezeptor-antagonisten
EA199800204A1 (ru) Антагонисты 5-нтрецепторов для лечения дискинезии
SE0303418D0 (sv) New use 1
PL1668027T3 (pl) Cykliczne peptydy działające jako antagoniści Urotensyny-II